BSE Pharma Sector Regulatory Filings — October 19, 2026

Board meets November 4, 2026 to approve Q2 FY27 and H1 FY27 unaudited results; results are the next hard data point for the stock, with no pre-announced figures to judge direction

Q2 FY27 earnings call scheduled for November 4, 2026 at 18:00 IST via Zoom, giving management a forum to discuss the quarter and commentary on outlook within a day of the board meeting

Trading window closed October 1, 2026 and reopens November 6, 2026, 48 hours after results declaration; window timing is standard and no insider transactions were disclosed

Trading window remains closed until November 6 and reopens November 9, 2026 for Directors and Designated Persons; the three-day gap versus Lupin's reopening is a procedural difference, not a signal

Both Lupin (November 3 board) and Zydus (November 4 board) report Q2 FY27 within the same two-day window, so sector-wide earnings sentiment will be driven by a concentrated set of results and any shared commentary on US generics pricing or regulatory matters

Trading window stays closed for promoters, directors and KMP through November 6, limiting insider participation in the period immediately around results; no pledge or insider holding data was disclosed in this batch to assess conviction

Trading window stays closed through November 9 for Directors and Designated Persons, the longer of the two windows in this batch; the filing itself provides no financial detail to gauge performance ahead of results

November 4, 2026 call at 18:00 IST offers an opportunity to assess management commentary on quarterly performance and forward guidance; analysts should prepare questions on margin trajectory and pipeline

November 4 board meeting to approve H1 FY27 results is a scheduled catalyst; investors can position around the release with no prior guidance to anchor expectations

Two index constituents reporting within 48 hours offers a compact read on the sector's Q2 execution, allowing comparison of margin and growth outcomes between Lupin and Zydus once both are published

Lupin and Zydus both scheduled board meetings for November 3-4, 2026 to approve Q2 FY27 results, indicating a concentrated reporting window for the Pharma index with the market likely to read the two as a joint sector signal

Both companies filed trading-window closure notices under SEBI insider trading regulations (Regulation 29 and related provisions), reflecting uniform pre-results compliance practice across index constituents rather than any company-specific development

Results approval on Tuesday, November 3, 2026; key items to monitor are revenue growth, margin trend, and US generics commentary

Results and other items to be considered on Wednesday, November 4, 2026; watch for any change in guidance or pipeline updates

Wednesday, November 4, 2026 at 18:00 IST via Zoom; management commentary on outlook and any guidance revisions

Insider trading window reopens Friday, November 6, 2026; watch for post-results insider transactions as a conviction signal

Window reopens Monday, November 9, 2026 for Directors and Designated Persons; monitor for insider activity after the results release

Compare Lupin and Zydus Q2 FY27 margin and growth outcomes once both are published to gauge relative sector execution